Alembic announces USFDA final approval for single-dose vials
Doxorubicin Hydrochloride Liposome Injection is indicated for the treatment of Ovarian Cancer, AIDS-Related Kaposi's Sarcoma, and Multiple Myeloma
Doxorubicin Hydrochloride Liposome Injection is indicated for the treatment of Ovarian Cancer, AIDS-Related Kaposi's Sarcoma, and Multiple Myeloma
Extended lab space for product development, customer demos, and training
The approval in China is supported by a robust local clinical development program confirming the drug’s safety, tolerability, and efficacy profile
Eylea 8 mg is the first and only anti-vascular endothelial growth factor (VEGF) treatment in the EU with treatment intervals of up to 6 months for both patients with nAMD and DME
Prucalopride Tablets are bioequivalent to Motegrity Tablets, 1 mg and 2 mg, of Takeda Pharmaceuticals USA
Viatel bioresorbable polymers are increasingly used in dental and orthopedic implants
Prucalopride Tablets are indicated for the treatment of chronic idiopathic constipation in adults
BASF strengthens its commitment to the biopharma and pharmaceutical ingredients industries through a new investment in North America
This is the second and final phase of the overall capacity addition of ?195 kL which was under construction at Unit IV Bidar facility
The CR Bio unit represents a non-core legacy asset with limited strategic alignment to our core CDMO operations
Subscribe To Our Newsletter & Stay Updated